Key opinion leaders review clinical cases in triple-negative breast cancer, focusing on recent advances, treatment options, and clinical trials impacting the treatment.
EP. 1: Case 1: 53-Year-Old Woman With TNBC
Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.
EP. 2: Case 1: IMpassion 130 Trial Design and Results
Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.
EP. 3: Case 1: KEYNOTE-355 Trial Design and Considerations
The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.
EP. 4: Case 1: Treatment Recommendations for PD-L1+ TNBC
The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.
EP. 5: Case 2: 34-Year-Old Woman With TNBC
Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.
EP. 6: Case 2: Considerations for PARP Inhibitor Use in TNBC
Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.
EP. 7: Case 2: Study Design and Data for PARP Inhibitors in TNBC
Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.
EP. 8: Case 3: 48-Year-Old Woman With Stage T2N1 TNBC
Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.
EP. 9: Case 3: Implications of Residual Disease on TNBC Outcomes
Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.
EP. 10: Case 3: Residual Disease in TNBC and Treatment Considerations
The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.
EP. 11: Case 3: Practical Considerations for Use of Sacituzumab Govitecan
Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.
EP. 12: Case 3: Precision Medicine in Metastatic Breast Cancer
Experts in the field of breast cancer review the role of genetic testing in the selection of treatment for patients with TNBC.
EP. 13: Case 3: Clinical Trial Inclusion in TNBC: Considerations and Barriers
The panel of experts in breast cancer discuss enrollment of patients with TNBC in clinical trials, including considerations and barriers.
EP. 14: Metastatic TNBC Case Overview
Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.
EP. 15: Early Stage Options for Patients With Metastatic TNBC
Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.
EP. 16: IMpassion130 and KEYNOTE-355 Trials in Patients With Metastatic TNBC: Part 1
An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.
EP. 17: IMpassion130 and KEYNOTE-355 Trials in Patients With Metastatic TNBC: Part 2
Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.
EP. 18: Germline BRCA1/2 Mutations in Metastatic TNBC
Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.
EP. 19: Immune-Related Adverse Effects of ICI Therapies in Metastatic TNBC
An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.
EP. 20: Clinical Pearls for Treating Patients With Metastatic TNBC
Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.
2 Clarke Drive Cranbury, NJ 08512